A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

NCT05699239 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

326

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperphosphatemia Patients on Hemodialysis

Interventions

DRUG: TS-172 10mg bid
DRUG: TS-172 30mg bid
DRUG: TS-172 60mg bid
DRUG: TS-172 20mg tid
DRUG: Placebo

Sponsor

Taisho Pharmaceutical Co., Ltd.